Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Study On Schedule for Topline Data this Quarter

HAYWARD, Calif., Jan. 22, 2018 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for the RESULT Phase 3 clinical study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency (“EPI”). The second, and final, interim futility analysis was conducted by RESULT’s Data Monitoring Committee which is comprised of experts appointed by the Cystic Fibrosis Foundation’s Therapeutics Development Network. Anthera completed patient recruitment of the RESULT study in November 2017 and is on track to report topline data later this quarter.

"The positive interim futility analysis of the RESULT study represents one of the last clinical milestones ahead of topline data this quarter," shared Craig Thompson, President & CEO of Anthera. “We look forward to sharing the study outcome shortly and potentially providing patients with a new treatment option for their exocrine pancreatic insufficiency therapy.”

Sollpura has the potential to become the first non-porcine pancreatic enzyme replacement therapy (PERT) which may provide a reduction in the size and number of pills for patients with EPI.

About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and B-cell associated renal diseases. Additional information on Anthera can be found at www.anthera.com.

Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend, “anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including but not limited to those set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT:
Investor Relations of Anthera Pharmaceuticals, Inc.
[email protected]

For Media Inquiries:
Frannie Marmorstein, 305-567-0821
[email protected]

www.twitter.com/antherapharma 
https://www.facebook.com/antherapharma/ 
https://www.linkedin.com/company/anthera-pharmaceuticals 
Source: Anthera Pharmaceuticals, Inc.